Cipla shares drop 2% after US FDA approves rival's generic Advair inhaler. Aurobindo Pharma's Lannett acquisition may raise US revenue by $30-40 million Cipla seeks FDA approval for generic Advair, ...

This product is used to control and prevent symptoms (wheezing and shortness of breath) caused by asthma. It contains 2 medications: fluticasone and salmeterol. Fluticasone belongs to a class of drugs ...

Chronic obstructive pulmonary disease, or COPD, is an ongoing group of lung conditions that include chronic bronchitis and emphysema. COPD is the result of damaged lung tissue, which leads to ...

Mona Bafadhel receives funding from the National Institute of Health Research, Asthma+Lung UK, and Horizon Europe. For this study, Mona Bafadhel received funding from AstraZeneca to complete the study ...

A new study shows that a form of vitamin B3 can reduce lung inflammation in COPD patients. The researchers hope it will pave the way for new treatment options. We live longer and longer, and as we age ...

Inhalers prescribed to Centers for Medicare & Medicaid Services (CMS) beneficiaries for asthma and chronic obstructive pulmonary disease resulted in estimated emissions of greenhouse gases equivalent ...

The triple therapy of budesonide, glycopyrrolate, and formoterol fumarate showed the greatest incremental net benefit among a series of triple therapy medications that were evaluated against dual ...

No, “HFA loan” is not a misidentification of the better-known FHA loan. It’s a wholly different type of mortgage, offered through state housing finance agencies (HFAs) in partnership with major loan ...

Advair is a combination of two medications, fluticasone and salmeterol, that helps people manage asthma and chronic obstructive pulmonary disease (COPD). By following these 15 steps, you can ensure ...

Three of the world’s four largest producers of inhalers have agreed to cap the price of their inhaler products and similar medicines at $35 a month for U.S. buyers following pressure from Sen. Bernie ...

GSK plc GSK announced plans to cap out-of-pocket expenses for its inhaled respiratory portfolio in the United States at $35 per month, following a similar move by rivals AstraZeneca AZN and Boehringer ...

On Wednesday, GSK Plc (NYSE:GSK) announced it will cap out-of-pocket costs for eligible patients at no more than $35 per month for all its asthma and chronic obstructive pulmonary disease (COPD) ...